All Blogs

Mar 28, 2023

Novartis Announces the Positive Results of Phase III NATALEE trial Evaluating Kisqali Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/hu...

Mar 23, 2023

Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm On March 21, 2023, Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to ...

Mar 31, 2023

Peripheral artery disease (PAD) is one of the leading causes of cardiovascular morbidity, affecting 12-14% of the world’s population. Peripheral artery disease affects six times more people worldwide than HIV. 1 in 3 diabetics over age 50 suffer from peripheral artery disease. In addition, 1 in every 20 Americans o...

Mar 27, 2023

Triglycerides, the energy-providing lipids consumed from fat-containing food, have been known to cause severe health conditions in high levels, including acute pancreatitis. It is also associated with apolipoprotein C-III (APOCIII) and high probability of coronary artery disease (CAD). Triglyceride levels above a c...

Mar 24, 2023

With the onset of the fourth industrial revolution in the twenty-first century, a new branch emerged: Robotics. Robotics is the amalgam of computer science and engineering to make programmable machines that aim to assist humans in their tasks and produce results with minimum error. From space science to healthcare ...

Mar 22, 2023

Musculoskeletal disorders are one of the most common disorders affecting a significant proportion of the population worldwide. They can have severe long-term pain, high levels of physical disability, various types of psychological distress, and reduced quality of life. As per the WHO (2022), musculoskeletal conditi...

Mar 21, 2023

AbbVie Announces Positive Results of Study Evaluating SKYRIZI in Plaque Psoriasis Patients AbbVie announced new 52-week data from an open-label, a single-arm study demonstrating improved plaque psoriasis signs and symptoms in a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 ...

Mar 16, 2023

Ergo-Series of the OMNI® Surgical System Launched by Sight Sciences On March 9, 2023, Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology, providing solutions for transforming care and improving patients' lives, announced the launch of the Ergo-Seri...

Mar 20, 2023

Obesity is the second most common cause of preventable death, associated with the risk of developing inflammatory components, directly and indirectly, related to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. ...

Mar 17, 2023

Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative marke...